Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708110 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00708110 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 35 participants.
The verdict
NCT00708110, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-controlled 'proof of concept' study is to be conducted to compare antiviral effect, safety, tolerability, and pharmacokinetics of GSK1349572 monotherapy versus placebo over 10 days in ART-naïve and experienced, but integrase inhibitor naïve (meaning never having had an integrase inhibitor) HIV-1 infected adults who are not currently receiving antiretroviral therapy. This study consists of a screening visit, a treatment period and a follow-up evaluation. Thirty subjects will be randomized to receive one of three doses of GSK1349572 or placebo q24h over 10 days. Antiviral effect measures include viral load and CD4 cell count.
Interventions
- DRUG Placebo
- DRUG GSK1349572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00708110
The ClinicalTrials.gov registry entry for NCT00708110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00708110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00708110 about?
NCT00708110 is a clinical study titled "Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults". GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-controlled 'proof of concept' study is to be conducted to compare antiviral effect, safety, tolerability, and pharmac...
What is the current status of trial NCT00708110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00708110?
The interventions under investigation include: Placebo (DRUG), GSK1349572 (DRUG).
Who is sponsoring clinical trial NCT00708110?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.